---
title: "The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent… — report author — DecisionGateway"
description: "statement by report author, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad"
meta:
  "og:description": "statement by report author, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent… — report author — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.**

A statement by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *600mg 지속 투여군의 ACR20 값이 92.5%를 기록하여 절대적 수치 측면에서도 우수한 효능 입증*

companyreportPublished 2026-11-10 [ Read source](https://t.me/companyreport/116013)

## **Related claims**

[**In the 600mg high-dose maintenance group, the ACR20 response rate was 92.5%, with nearly all patients maintaining response through week 28.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db21-760b-a0d0-62b887471209) [**In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved statistical significance (p-value), a surprise exceeding market expectations.**report author · statement](https://dgw.tmarket.io/claims/01a1d4b6-f6d1-7aec-8105-c4689a803513) [**The 300mg low-dose group showed no maintenance effect: patients falling below ACR20 were 3 of 40 (7.5%) in 600mg, 9 of 36 (25.0%) in 300mg, and 10 of 41 (24.4%) in placebo, meaning the low-dose group was effectively without efficacy.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db33-7a9f-9f6e-fdb4decb1caa) [**In the D2T RA Phase 2b Period 2 results, the 600mg continuous dosing group achieved a p-value.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-398b-7bf3-a65b-cf8bdaaf0349) [**ACR20 reached 92.5%, surpassing 72.7% at week 16 and meeting expectations.**하나증권 제약/바이오 김선아 · statement](https://dgw.tmarket.io/claims/01a1d887-39a1-7a6b-bd1a-2c21ac06e0c4) [**IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.**현대차증권 제약/바이오/의료기기 김현석 · statement](https://dgw.tmarket.io/claims/01a1d950-db09-704e-b002-22ff5c6d58f3)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts from 4,500+ Telegram channels — every claim cited. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad#webpage","@type":"WebPage","description":"statement by report author, recorded recently — verbatim quote and source citation.","name":"The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent… — report author — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"The 600mg continuous dosing group recorded an ACR20 value…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-10","isBasedOn":"https://t.me/companyreport/116013","text":"600mg 지속 투여군의 ACR20 값이 92.5%를 기록하여 절대적 수치 측면에서도 우수한 효능 입증","url":"/claims/01a1d4b6-f6e3-7be5-ab83-bf2b785418ad"}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.